Cell-based therapies for the treatment of idiopathic pulmonary fibrosis (IPF) disease

Maliheh Ghadiri*, Paul M. Young, Daniela Traini

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

25 Citations (Scopus)


Introduction: During the last few decades, cell-based therapies have shown great potential to treat patients with lung diseases. It has been proposed that the administration of cells into an injured lung could be considered as a therapeutic method to repair and replace lost lung tissue. Using this method, transplanted cells with the ability to proliferate and differentiate into alveolar cells, have been suggested as a therapeutic strategy for IPF treatment.Areas covered: In this review, the latest investigations using various types of cells for IPF therapy have been presented. The cells studied for cell-based therapies in IPF are lung alveolar epithelial cells, lung resident stem cells and exogenous adult stem cells such as MSCs.Expert opinion: After many years of investigation, the use of cell-based therapies to treat IPF is still at the experimental phase. Problems include bioethical issues, safety of cell transplantation, routes of delivery and the dose and timing of administration. Further investigations are necessary to establish the best strategy for using cell-based therapies effectively for the treatment of IPF.

Original languageEnglish
Pages (from-to)375-387
Number of pages13
JournalExpert Opinion on Biological Therapy
Issue number3
Publication statusPublished - 3 Mar 2016
Externally publishedYes


  • Alveolar epithelial cell
  • Idiopathic pulmonary fibrosis
  • IPF
  • Stem cell


Dive into the research topics of 'Cell-based therapies for the treatment of idiopathic pulmonary fibrosis (IPF) disease'. Together they form a unique fingerprint.

Cite this